|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou G: Tobacco, air pollution,
environmental carcinogenesis, and thoughts on conquering strategies
of lung cancer. Cancer Biol Med. 16:700–713. 2019.
|
|
7
|
Anji A and Kumari M: Guardian of Genetic
Messenger-RNA-Binding Proteins. Biomolecules. 6:42016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pereira B, Billaud M and Almeida R:
RNA-Binding Proteins in Cancer: Old Players and New Actors. Trends
Cancer. 3:506–528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fox RG, Park FD, Koechlein CS, Kritzik M
and Reya T: Musashi signaling in stem cells and cancer. Annu Rev
Cell Dev Biol. 31:249–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lan L, Xing M, Douglas JT, Gao P, Hanzlik
RP and Xu L: Human oncoprotein Musashi-2 N-terminal RNA recognition
motif backbone assignment and identification of RNA‑binding pocket.
Oncotarget. 8:106587–106597. 2017. View Article : Google Scholar :
|
|
11
|
Liu Y, Fan Y, Wang X, Huang Z, Shi K and
Zhou B: Musashi-2 is a prognostic marker for the survival of
patients with cervical cancer. Oncol Lett. 15:5425–5432.
2018.PubMed/NCBI
|
|
12
|
Kudinov AE, Karanicolas J, Golemis EA and
Boumber Y: Musashi RNA-Binding Proteins as Cancer Drivers and Novel
Therapeutic Targets. Clin Cancer Res. 23:2143–2153. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ito T, Kwon HY, Zimdahl B, Congdon KL,
Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, et al:
Regulation of myeloid leukaemia by the cell-fate determinant
Musashi. Nature. 466:765–768. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kharas MG, Lengner CJ, Al-Shahrour F,
Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R,
et al: Musashi-2 regulates normal hematopoiesis and promotes
aggressive myeloid leukemia. Nat Med. 16:903–908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang S, Li N, Yousefi M, Nakauka‑Ddamba A,
Li F, Parada K, Rao S, Minuesa G, Katz Y, Gregory BD, et al:
Transformation of the intestinal epithelium by the MSI2 RNA-binding
protein. Nat Commun. 6:65172015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kudinov AE, Deneka A, Nikonova AS, Beck
TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, et
al: Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins
to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl
Acad Sci USA. 113:6955–6960. 2016. View Article : Google Scholar
|
|
17
|
Zhang MR, Xi S, Shukla V, Hong JA, Chen H,
Xiong Y, Ripley RT, Hoang CD and Schrump DS: The Pluripotency
Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy. Ann Am
Thorac Soc. 15(Suppl 2): S1242018. View Article : Google Scholar
|
|
18
|
Kang MH, Jeong KJ, Kim WY, Lee HJ, Gong G,
Suh N, Győrffy B, Kim S, Jeong SY, Mills GB, et al: Musashi
RNA-binding protein 2 regulates estrogen receptor 1 function in
breast cancer. Oncogene. 36:1745–1752. 2017. View Article : Google Scholar
|
|
19
|
Dong P, Xiong Y, Hanley SJB, Yue J and
Watari H: Musashi-2, a novel oncoprotein promoting cervical cancer
cell growth and invasion, is negatively regulated by p53-induced
miR-143 and miR-107 activation. J Exp Clin Cancer Res. 36:1502017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo K, Cui J, Quan M, Xie D, Jia Z, Wei D,
Wang L, Gao Y, Ma Q and Xie K: The Novel KLF4/MSI2 Signaling
Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Clin
Cancer Res. 23:687–696. 2017. View Article : Google Scholar :
|
|
21
|
Li Z, Jin H, Mao G, Wu L and Guo Q: Msi2
plays a carcinogenic role in esophageal squamous cell carcinoma via
regulation of the Wnt/β-catenin and Hedgehog signaling pathways.
Exp Cell Res. 361:170–177. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He L, Zhou X, Qu C, Hu L, Tang Y, Zhang Q,
Liang M and Hong J: Musashi2 predicts poor prognosis and invasion
in hepatocellular carcinoma by driving epithelial-mesenchymal
transition. J Cell Mol Med. 18:49–58. 2014. View Article : Google Scholar
|
|
23
|
Yang C, Zhang W, Wang L, Kazobinka G, Han
X, Li B and Hou T: Musashi-2 promotes migration and invasion in
bladder cancer via activation of the JAK2/STAT3 pathway. Lab
Invest. 96:950–958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee J, An S, Choi YM, Lee J, Ahn KJ, Lee
JH, Kim TJ, An IS and Bae S: Musashi-2 is a novel regulator of
paclitaxel sensitivity in ovarian cancer cells. Int J Oncol.
49:1945–1952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Tan S, Wang J, Chen S, Quan J,
Xian J, Zhang S, He J and Zhang L: Musashi2 modulates K562 leukemic
cell proliferation and apoptosis involving the MAPK pathway. Exp
Cell Res. 320:119–127. 2014. View Article : Google Scholar
|
|
26
|
Han Y, Ye A, Zhang Y, Cai Z, Wang W, Sun
L, Jiang S, Wu J, Yu K and Zhang S: Musashi-2 Silencing Exerts
Potent Activity against Acute Myeloid Leukemia and Enhances
Chemosensitivity to Daunorubicin. PLoS One. 10:e01364842015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lan L, Liu H, Smith AR, Appelman C, Yu J,
Larsen S, Marquez RT, Wu X, Liu FY, Gao P, et al: Natural product
derivative Gossypolone inhibits Musashi family of RNA-binding
proteins. BMC Cancer. 18:8092018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Minuesa G, Albanese SK, Xie W, Kazansky Y,
Worroll D, Chow A, Schurer A, Park SM, Rotsides CZ, Taggart J, et
al: Small-molecule targeting of MUSASHI RNA-binding activity in
acute myeloid leukemia. Nat Commun. 10:26912019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hong J and Luesch H: Largazole: From
discovery to broad-spectrum therapy. Nat Prod Rep. 29:449–456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar
|
|
31
|
Zeng X, Yin B, Hu Z, Liao C, Liu J, Li S,
Li Z, Nicklaus MC, Zhou G and Jiang S: Total synthesis and
biological evaluation of largazole and derivatives with promising
selectivity for cancers cells. Org Lett. 12:1368–1371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y,
Feng TT, Meng FY, Liu XL, Jiang QL, et al: Synergy between
proteasome inhibitors and imatinib mesylate in chronic myeloid
leukemia. PLoS One. 4:e62572009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Taori K, Paul VJ and Luesch H: Structure
and activity of largazole, a potent antiproliferative agent from
the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc.
130:1806–1807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu LC, Wen ZS, Qiu YT, Chen XQ, Chen HB,
Wei MM, Liu Z, Jiang S and Zhou GB: Largazole Arrests Cell Cycle at
G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung
Cancer Cells. ACS Med Chem Lett. 4:921–926. 2013. View Article : Google Scholar
|
|
35
|
Li N, Yousefi M, Nakauka-Ddamba A, Li F,
Vandivier L, Parada K, Woo DH, Wang S, Naqvi AS, Rao S, et al: The
Msi Family of RNA-Binding Proteins Function Redundantly as
Intestinal Oncoproteins. Cell Rep. 13:2440–2455. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saxton RA and Sabatini DM: mTOR Signaling
in Growth, Metabolism, and Disease. Cell. 169:361–371. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shimobayashi M and Hall MN: Making new
contacts: The mTOR network in metabolism and signalling crosstalk.
Nat Rev Mol Cell Biol. 15:155–162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar
|
|
40
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fang T, Lv H, Wu F, Wang C, Li T, Lv G,
Tang L, Guo L, Tang S, Cao D, et al: Musashi 2 contributes to the
stemness and chemore-sistance of liver cancer stem cells via LIN28A
activation. Cancer Lett. 384:50–59. 2017. View Article : Google Scholar
|
|
42
|
Choi YM, Kim KB, Lee JH, Chun YK, An IS,
An S and Bae S: DBC2/RhoBTB2 functions as a tumor suppressor
protein via Musashi-2 ubiquitination in breast cancer. Oncogene.
36:2802–2812. 2017. View Article : Google Scholar :
|
|
43
|
Ouyang SW, Liu TT, Liu XS, Zhu FX, Zhu FM,
Liu XN and Peng ZH: USP10 regulates Musashi-2 stability via
deubiquiti-nation and promotes tumour proliferation in colon
cancer. FEBS Lett. 593:406–413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Belew MS, Bhatia S, Keyvani Chahi A,
Rentas S, Draper JS and Hope KJ: PLAG1 and USF2 Co-regulate
Expression of Musashi-2 in Human Hematopoietic Stem and Progenitor
Cells. Stem Cell Reports. 10:1384–1397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Minuesa G, Antczak C, Shum D, Radu C,
Bhinder B, Li Y, Djaballah H and Kharas MG: A 1536‑well
fluorescence polarization assay to screen for modulators of the
MUSASHI family of RNA-binding proteins. Comb Chem High Throughput
Screen. 17:596–609. 2014. View Article : Google Scholar
|
|
46
|
Schnekenburger M, Dicato M and Diederich
M: Epigenetic modulators from "The Big Blue": A treasure to fight
against cancer. Cancer Lett. 351:182–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pilon JL, Clausen DJ, Hansen RJ, Lunghofer
PJ, Charles B, Rose BJ, Thamm DH, Gustafson DL, Bradner JE and
Williams RM: Comparative pharmacokinetic properties and antitumor
activity of the marine HDACi Largazole and Largazole peptide
isostere. Cancer Chemother Pharmacol. 75:671–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu Y, Salvador LA, Byeon S, Ying Y, Kwan
JC, Law BK, Hong J and Luesch H: Anticolon cancer activity of
largazole, a marine-derived tunable histone deacetylase inhibitor.
J Pharmacol Exp Ther. 335:351–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
